Searchable abstracts of presentations at key conferences in endocrinology

ea0081p129 | Endocrine-Related Cancer | ECE2022

The impact of pregnancy on disease outcome in patients with persistent differentiated thyroid carcinoma

Giancola Noemi , Colombo Carla , De Leo Simone , Trevisan Matteo , Persani Luca , Fugazzola Laura

Background: Pregnancy does not cause differentiated thyroid cancer (DTC) recurrence in patients without structural or biochemical evidence of disease at the time of conception. However, data regarding pregnancy’s impact in patients with persistent DTC before conception are still controversial.Aim: The aim of the study was to determine whether pregnancy could significantly influence the outcome in DTC patients in persistence before pregnancy, but wit...

ea0081p138 | Pituitary and Neuroendocrinology | ECE2022

Takayasu’s artheritis presenting as a large sellar mass with neurological and hypopituitarism manifestations

Galazzi Elena , Giancola Noemi , Citterio Valeria , Moro Mirella , Addobbati Laura , Avignone Sabrina , Capsoni Franco , Persani Luca

Introduction: Only one case of hypophysitis secondary to Takayasu’s artheritis (TKA) has been described so far. We report the second case of a TKA presenting with a massive sellar and cerebrovascular infiltration.Clinical case: A 52 years-old female was referred to endocrine outpatient clinics after a brain MRI performed for a 2-year history of headaches, dizziness and general discomfort. Past medical history included hypertension and aspecific symp...

ea0081p746 | Thyroid | ECE2022

Lenvatinib-induced hypocalcaemia due to transient hypoparathyroidism: a case-report

Trevisan Matteo , Colombo Carla , Giancola Noemi , Persani Luca , Fugazzola Laura , De Leo Simone

Radioiodine refractory differentiated thyroid cancer can be effectively treated with multi-tyrosine-kinase inhibitors (mTKI). Due to their pleiotropic mechanism of action, these drugs may cause different side effects. Hypocalcaemia has been reported in up to 35% of patients treated with mTKI, but little is known about its pathophysiology and clinical relevance. We report the case of a 78 years old woman treated for a multifocal papillary thyroid cancer, infiltrating perithyroi...

ea0084op-03-15 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Assessment of adrenal function in a large series of patients confirms that adrenal insufficiency is a common cause of fatigue during treatment with multikinase inhibitors (MKIS)

Colombo Carla , De Leo Simone , Giancola Noemi , Trevisan Matteo , Persani Luca , Fugazzola Laura

Background: Fatigue is one of the most frequently reported adverse events in patients treated with multikinase inhibitors (MKIs). It is present in about 59% and 24% of patients treated with lenvatinib and vandetanib, respectively, associates with a decreased quality of life and often leads to treatment discontinuation. In 2018, for the first time, a correlation between fatigue and primary adrenal insufficiency (PAI) was demonstrated in 12 patients treated with lenvatinib and v...

ea0084op-10-51 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Hypocalcemia is a frequent and life-threatening effect during lenvatinib treatment

Trevisan Matteo , Moneta Claudia , Colombo Carla , Giancola Noemi , Persani Luca , Fugazzola Laura , De Leo Simone

Objectives: Lenvatinib treatment is responsible for several adverse events (AEs). Hypocalcemia has been described in the registration study in 7% of patients, being of grade ≥3 in 2.7% of cases. No real-life studies are available, and the actual impact of this AE during Lenvatinib treatment is still unknown. Aim of our study is to evaluate the frequency of hypocalcemia in our series of patients treated with Lenvatinib and the possible predictors of this side effect.<...

ea0084ps3-14-129 | Thyroid Cancer CLINICAL 2 | ETA2022

Hypocalcaemia secondary to lenvatinib induced-hypoparathyroidism: a case-report

Moneta Claudia , Trevisan Matteo , Colombo Carla , Giancola Noemi , Persani Luca , Fugazzola Laura , De Leo Simone

In the last decades, multi-tyrosine-kinase inhibitors (mTKI) have emerged as an effective treatment for radioiodine refractory differentiated thyroid cancer. Due to their pleiotropic mechanism of action, these drugs may cause different side effects. Hypocalcaemia has been reported in up to 35% of patients treated with mTKI, but up to date little is known about its pathophysiology and relevance. We report the case of a 78 years old woman operated on for a papillary thyroid canc...